Evidence map›Paper›PMID 27048470›Full record

ArticleJournal of neuroinflammation2016

Activation of the NLRP3 inflammasome in lipopolysaccharide-induced mouse fatigue and its relevance to chronic fatigue syndrome.

Zi-Teng Zhang, Xiu-Ming Du, Xiu-Juan Ma, Ying Zong, Ji-Kuai Chen, Chen-Lin Yu, Yan-Gang Liu, Yong-Chun Chen, Li-Jun Zhao, Guo-Cai Lu

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Aloifol I Derived fromACS pharmacology & translational science · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Nutrients · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zi-Teng ZhangDepartment of Health Toxicology, College of Tropical Medicine and Public Health, Second Military Medical University, Shanghai, 200433, China.
Xiu-Ming DuDepartment of Health Toxicology, College of Tropical Medicine and Public Health, Second Military Medical University, Shanghai, 200433, China.
Xiu-Juan MaDepartment of Health Toxicology, College of Tropical Medicine and Public Health, Second Military Medical University, Shanghai, 200433, China.
Ying ZongDepartment of Health Toxicology, College of Tropical Medicine and Public Health, Second Military Medical University, Shanghai, 200433, China.
Ji-Kuai ChenDepartment of Health Toxicology, College of Tropical Medicine and Public Health, Second Military Medical University, Shanghai, 200433, China.
Chen-Lin YuLaboratory Animal Center, Second Military Medical University, Shanghai, 200433, China.
Yan-Gang LiuDepartment of Health Toxicology, College of Tropical Medicine and Public Health, Second Military Medical University, Shanghai, 200433, China.
Yong-Chun ChenDepartment of Health Toxicology, College of Tropical Medicine and Public Health, Second Military Medical University, Shanghai, 200433, China.
Li-Jun ZhaoDepartment of Respiratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China. zlj6583@163.com.
Guo-Cai LuDepartment of Health Toxicology, College of Tropical Medicine and Public Health, Second Military Medical University, Shanghai, 200433, China. newdrug@smmu.edu.cn.
Second Military Medical University · CNChanghai Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe NLRP3 inflammasome (NOD-like receptor family, pyrin domain containing 3) is an intracellular protein complex that plays an important role in innate immune sensing. Its activation leads to the maturation of caspase-1 and regulates the cleavage of interleukin (IL)-1β and IL-18. Various studies have shown that activation of the immune system plays a pivotal role in the development of fatigue. However, the mechanisms underlying the association between immune activation and fatigue remained elusive, and few reports have described the involvement of NLRP3 inflammasome activation in fatigue.

methodsWe established a mouse fatigue model with lipopolysaccharide (LPS, 3 mg/kg) challenge combined with swim stress. Both behavioural and biochemical parameters were measured to illustrate the characteristics of this model. We also assessed NLRP3 inflammasome activation in the mouse diencephalon, which is the brain region that has been suggested to be responsible for fatigue sensation. To further identify the role of NLRP3 inflammasome activation in the pathogenesis of chronic fatigue syndrome (CFS), NLRP3 KO mice were also subjected to LPS treatment and swim stress, and the same parameters were evaluated.

resultsMice challenged with LPS and subjected to the swim stress test showed decreased locomotor activity, decreased fall-off time in a rota-rod test and increased serum levels of IL-1β and IL-6 compared with untreated mice. Serum levels of lactic acid and malondialdehyde (MDA) were not significantly altered in the treated mice. We demonstrated increased NLRP3 expression, IL-1β production and caspase-1 activation in the diencephalons of the treated mice. In NLRP3 KO mice, we found remarkably increased locomotor activity with longer fall-off times and decreased serum IL-1β levels compared with those of wild-type (WT) mice after LPS challenge and the swim stress test. IL-1β levels in the diencephalon were also significantly decreased in the NLRP3 KO mice. By contrast, IL-6 levels were not significantly altered.

conclusionsThese findings suggest that LPS-induced fatigue is an IL-1β-dependent process and that the NLRP3/caspase-1 pathway is involved in the mechanisms of LPS-induced fatigue behaviours. NLRP3/caspase-1 inhibition may be a promising therapy for fatigue treatment.

Indexed as

AnimalsBehavior, AnimalDisease Models, AnimalFatigueFatigue Syndrome, ChronicFemaleInflammasomesInterleukin-1betaInterleukin-6LipopolysaccharidesMiceMice, Inbred C57BLMice, KnockoutNLR Family, Pyrin Domain-Containing 3 ProteinStress, PsychologicalSwimmingInflammasomesInterleukin-1betaInterleukin-6LipopolysaccharidesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseChronic fatigue syndromeIL-1βLPSNLRP3 inflammasomeNLRP3 knockout mice

Identifiers

PMID27048470
PMCPMC4822300
OpenAlexW2327761940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.